Medicines planning
46 results
Applied filters
Preparing to use denosumab 60mg biosimilar
1 October 2026Biosimilars of denosumab 60mg (Prolia) are available. We offer general information and implementation advice.
Preparing to use denosumab 120mg biosimilar
1 October 2026Biosimilars of denosumab 120mg (Xgeva) are available. We offer general information and implementation advice.
Annual medicines planning publication, Prescribing Outlook
21 September 2026Our annual output ‘PO’ supports managed entry and budget planning for new medicines, new indications and medicines with loss of exclusivity in the NHS.
Biosimilar and key generic medicines – September 2026 update
16 September 2026An update around biosimilar and key generic medicines to support system planning and mobilisation.
Using our annual medicines planning publication, Prescribing Outlook
14 August 2026Users should be aware of the constraints and assumptions in creating Prescribing Outlook, as well as their responsibilities for use.
Preparing to use ustekinumab biosimilar
31 July 2026Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
The licence and supporting evidence for ustekinumab biosimilars
31 July 2026Ustekinumab biosimilars are available for use within the NHS. Learn about indications, formulations, supporting evidence and differences.
Preparing to use golimumab biosimilar
21 July 2026One golimumab biosimilar (Gobivaz) is available. We offer general information and implementation advice.
The licence and supporting evidence for omalizumab biosimilar
20 July 2026Adcomfo, a second omalizumab biosimilar alongside Omlyclo, is now licensed. Review its indications, evidence, and main differences.
Preparing to use omalizumab biosimilar
20 July 2026Adcomfo, a second omalizumab biosimilar alongside Omlyclo, is now licensed. We offer general information and implementation advice.